MABRIDGE: MabionCD20® Compared to MabThera® and Rituxan® in Patients With Rheumatoid Arthritis
Study Details
Study Description
Brief Summary
Primary objective of the study is to establish a 3-way PK similarity bridge between MabionCD20 (candidate biosimilar to rituximab), MabThera® (EU-sourced rituximab) and Rituxan® (US-sourced rituximab) following the administration of these drugs to patients with moderate-to-severe rheumatoid arthritis. Main secondary objective is to confirm therapeutic similarity between MabionCD20 and the reference rituximab.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 3 |
Detailed Description
Patients with active moderate-to-severe rheumatoid arthritis diagnosed according to the 2010 ACR criteria will be randomized to receive a blinded treatment course of either MabionCD20, EU-Rituximab (MabThera®) or US-Rituximab (Rituxan®) on the top of a stable methotrexate therapy. Two infusions of investigational drug at a dose of 1000 mg will be given at Day 1 and 15. Patients will be then followed for a minimum of 24 weeks to establish PK and therapeutic similarity and to compare PD, safety and immunogenicity parameters between the three rituximab products (Main Phase). Patients may receive a second course of investigational therapy at Week 24, provided that they meet re-treatment eligibility criteria specified in the study protocol. Subjects in MabionCD20 and EU-Rituximab groups will be continued on their assigned treatments, while all subjects in US-Rituximab group will be switched to MabionCD20. All subjects (re-treated and not re-treated) will continue the follow-up until Week 48 to collect long-term safety, immunogenicity and efficacy data.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: MabionCD20 / MabionCD20 Patients receive one or two treatment courses of MabionCD20, each consisting of two 1000 mg i.v. infusions at an interval of 14 days. Investigational drug will be administered at Day 1 and Day 15, and, if patient is eligible for re-treatment, also at Week 24 and Week 26. |
Biological: MabionCD20 (candidate biosimilar to rituximab)
Intravenous infusion, 10 mg/ml concentrate, 500 ml
Other Names:
|
| Active Comparator: EU-Rituximab / EU-Rituximab Patients receive one or two treatment courses of MabThera®, each consisting of two 1000 mg i.v. infusions at an interval of 14 days. Investigational drug will be administered at Day 1 and Day 15, and, if patient is eligible for re-treatment, also at Week 24 and Week 26. |
Biological: MabThera®
Intravenous infusion, 10 mg/ml concentrate, 500 ml
Other Names:
|
| Active Comparator: US-Rituximab / MabionCD20 Patients receive a single treatment course of Rituxan®, consisting of two 1000 mg i.v. infusions at Day 1 and Day 15. After 24 weeks of follow-up, all patients eligible for re-treatment, are switched to receive a single treatment course of MabionCD20, consisting of two 1000 mg i.v. infusions at Week 24 and Week 26. |
Biological: MabionCD20 (candidate biosimilar to rituximab)
Intravenous infusion, 10 mg/ml concentrate, 500 ml
Other Names:
Biological: Rituxan®
Intravenous infusion, 10 mg/ml concentrate, 500 ml
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Area Under the Serum Concentration-time Curve from Day 1 to Week 24, with extrapolation to infinity [AUC 0-inf (D1-W24)] [Day 1 to Week 24]
Concentration of rituximab in serum over the entire PK study duration, with extrapolation to infinity. Outcome based on all PK samples collected in the study - from Day 1 (first infusion) to Week 24 (before administration of the 2nd treatment course).
- Area Under the Serum Concentration-time Curve from Day 1 to Day 15 [AUC 0-t (D1-D15)] [Day 1 to Day 15]
Concentration of rituximab in serum measured from Day 1 (before the 1st drug infusion) to Day 15 (before the 2nd drug infusion).
Secondary Outcome Measures
- Mean Change from Baseline in DAS28-ESR score [Baseline to Week 48]
DAS28-ESR is a disease activity index calculated from the following variables: Tender joint count (28 joints); Swollen joint count (28 joints); Erythrocyte sedimentation rate (ESR); Patient's assessment of global disease activity. The score ranges from 0 to ca. 10 points, with > 5.1 indicating high disease activity, < 3.2 indicating low disease activity, and < 2.6 indicating clinical remission. Change from baseline to Week 24 will be used for the confirmation of therapeutic similarity. For the US submission, therapeutic similarity will be confirmed if 90% CI of the difference between MabionCD20 and the combined EU- plus US-Rituximab group is contained within (-0.6; +0.5) equivalence margin. For the EU submission, therapeutic similarity will be declared if 95% CI of the difference is contained within (-0.6; +0.6) margin. In an additional analysis, MabionCD20 group will be compared against EU-Rituximab group alone using the above EU criteria.
- Mean Change from Baseline in DAS28-CRP score [Baseline to Week 48]
DAS28-CRP is a disease activity index calculated from the following variables: Tender joint count (28 joints); Swollen joint count (28 joints); C-reactive protein (CRP); Patient's assessment of global disease activity. It ranges from 0 to ca. 10 points, with a score > 5.1 indicating high disease activity, a score < 3.2 indicating low disease activity, and a score < 2.6 indicating clinical remission of RA.
- Percentage of patients achieving an ACR20/50/70 response [Baseline to Week 48]
A positive ACR20/50/70 response is achieved, when all of the following improvement criteria are met: ≥ 20%/50%/70%* improvement in tender joint count. ≥ 20%/50%/70%* improvement in swollen joint count. ≥ 20%/50%/70%* improvement in minimum 3 of the following 5 parameters: Patient's assessment of pain; Patient's global assessment of disease activity; Physician's global assessment of disease activity; Patient's assessment of physical function (HAQ-DI); Laboratory evaluation of acute phase reactant (ESR) 20%, 50% and 70% improvement apply to ACR20, ACR50 and ACR70 response, respectively
- Percentage of patients with low disease activity (DAS28-ESR <3.2) [Baseline to Week 48]
DAS28 scale ranges from 0 to approximately 10 points, with a score higher than 5.1 indicating high disease activity, a score less than 3.2 indicating low disease activity, and a score less than 2.6 indicating clinical remission of RA.
- Percentage of patients with disease remission (DAS28-ESR <2.6) [Baseline to Week 48]
DAS28 scale ranges from 0 to approximately 10 points, with a score higher than 5.1 indicating high disease activity, a score less than 3.2 indicating low disease activity, and a score less than 2.6 indicating clinical remission of RA.
- Percentage of patients with a moderate response on EULAR scale [Baseline to Week 48]
There are three categories of EULAR response (good, moderate and non-responders) which include not only the individual's amount of change in the DAS but also the attainment of a particular DAS value (low, moderate or high) at the endpoint. To be classified as having a moderate EULAR response, the patient must demonstrate a minimum change from baseline on DAS28-ESR of > 0.6 to < 1.2, as well as the endpoint achievement of a DAS-28 ≤ 5.1.
- Percentage of patients with a good response on EULAR scale [Baseline to Week 48]
There are three categories of EULAR response (good, moderate and non-responders) which include not only the individual's amount of change in the DAS but also the attainment of a particular DAS value (low, moderate or high) at the endpoint. To be classified as having a good EULAR response, the patient must demonstrate a significant change from baseline (> 1.2) as well as reach low disease activity (DAS-28 ≤ 3.2).
- Simplified Disease Activity Index (SDAI) [Baseline to Week 48]
SDAI is composed of the following clinical and laboratory variables: tender joint count (up to 28 joints); swollen joint count (up to 28 joints); patient's assessment of global disease activity; physician's assessment of global disease activity; CRP (C-reactive protein). Summation of all above variables produces a SDAI score (maximum 86.0 points). High disease activity is defined on SDAI as a score higher than 26.0 points, while a cut-off for remission is set at 3.3 points.
- Clinical Disease Activity Index (CDAI) [Baseline to Week 48]
CDAI is calculated in the same way as SDAI, except that only clinical parameters of disease level are taken into account (without CRP). Maximum score is 76.0 points. High disease activity is defined above 22.0 points and remission as ≤ 2.8 points
- Area Under the Serum Concentration-time Curve from Day 1 to Week 24 [AUC 0-t (D1-W24)] [Baseline to Week 24]
Concentration of rituximab in serum over the entire PK study duration, without extrapolation to infinity. Outcome based on all PK samples collected in the study - from Day 1 (first infusion) to Week 24 (before administration of the 2nd treatment course).
- Area Under the Serum Concentration-time Curve from Day 15 to Week 24 [AUC 0-t (D15-W24)] [Day 15 to Week 24]
Concentration of rituximab in serum measured from Day 15 (before the 2nd drug infusion) to Week 24 (before the 2nd treatment course)
- Maximum drug concentration in serum after the 1st infusion (Cmax1) [Day 1]
Maximum drug concentration measured after the 1st study drug infusion at Day 1
- Maximum drug concentration in serum after the 2nd infusion (Cmax2) [Day 15]
Maximum drug concentration measured after the 2nd study drug infusion at Day 15
- Trough drug concentration in serum (Ctrough) [Day 15]
Drug concentration measured shortly before the 2nd study drug infusion at Day 15
- Time to achieve maximum drug concentration in serum after the 1st infusion (Tmax1) [Day 1]
Time to achieve maximum drug concentration in serum after the 1st infusion at Day 1
- Time to achieve maximum drug concentration in serum after the 2nd infusion (Tmax2) [Day 15]
Time to achieve maximum drug concentration in serum after the 2nd infusion at Day 15
- Absolute CD19+ B cell counts by visit [Day 1 to Week 24]
Evolution of CD19+ B cell counts from the 1st study drug infusion at Day 1 to Week 24
- Percentage of patients with undetectable levels of CD19+ B-cells [Day 3 and Week 24]
Percentage of patients who achieve a complete depletion of CD19+ B-cells two days after the 1st infusion (Day 3) and percentage of patients who remain depleted of CD19+ B-cells on Week 24
- Percentage of patients with Adverse Events (AEs) [Day 1 to Week 48]
Patients with AEs, which occurred after signing the Informed Consent Form (ICF) until the study end at Week 48. Several categories of AEs will be evaluated: Treatment-emergent adverse events (TEAEs, AEs occurring after the initiation of study treatment); Related TEAEs (classified as at least possibly related to the study drug by Investigators); Severe TEAEs; TEAEs leading to permanent/temporary discontinuation of the study drug or reduction in infusion rate; Treatment-emergent serious adverse events (TESAEs); Related TESAEs; TESAEs leading to permanent/temporary discontinuation or reduction in infusion rate; TEAEs leading to death; Adverse events of special interest (AESI), which include: Infusion-related reactions (IRRs), Hypersensitivity and allergic reactions, Infusion-associated cardiovascular events, Serious infection events, SARS-CoV-2 infections and Progressive multifocal leukoencephalopathy (PML).
- Percentage of patients with a positive anti-drug antibody (ADA) response [Day 1 to Week 48]
Positive ADA response is a composite of treatment-induced and treatment-boosted ADAs. Patients with persistent response will be distinguished from patients with transient ADAs. Patients with positive samples will be additionally analyzed for ADA titer and for the presence of drug neutralizing antibodies (percentage of patients with nAb).
Eligibility Criteria
Criteria
INCLUSION CRITERIA:
-
Male or female, age 18 - 80 years
-
Body Surface Area (BSA) between 1.5 and 2.2 m2
-
Confirmed diagnosis of RA diagnosed according to the revised (2010) ACR/EULAR classification criteria, with a disease duration minimum of 6 months prior to the Screening Visit
-
Currently moderate to severe RA despite ongoing administration of an adequate MTX regimen. Moderate to severe disease is defined here as the presence of the following two criteria:
-
Six or more swollen joints and ≥6 tender/painful joints, verified by a physician during the screening and re-confirmed at baseline visit (Day 1)
-
DAS28 score ≥3.2 at screening
-
No history of treatment with TNF-α inhibitor (innovative or biosimilar, authorized or investigational) at any time before the screening i.e. TNF-α inhibitor naive population.
-
Receiving MTX treatment at a dosage of 7.5-25 mg/week for at least 12 weeks prior to screening, with the last 4 weeks at a stable dose, and willing to remain at this dose for the entire study duration
-
Male or WOCBP must consent to use highly effective contraception, from the Screening Visit, during the intervention period, and for at least 12 months after the last dose of study intervention
-
Female participants must not be pregnant or lactating (negative baseline serum test)
EXCLUSION CRITERIA:
-
History of or current inflammatory joint disease other than RA
-
History of or current systemic autoimmune disorder
-
ACR functional class IV disease
-
History of psychiatric disorder that would interfere with normal participation in the study
-
Evidence of HBV, HCV, HIV infection
-
Evidence of laboratory-confirmed or clinically suspected SARS-CoV-2 infection within 14 days before the study drug administration and a documented positive RT-PCR test within 72 hours before the first infusion or positive antigen test within 24 hours before the first infusion.
-
Serious and/or uncontrolled coexisting diseases which are recognized as major contraindications to the administration of rituximab, methotrexate or any of the pre-medication components or as important risk factors for the development of severe or life-threatening SARS-CoV-2 infection or other factors, which in the Investigator's opinion, would preclude patients participation. This category includes severe pulmonary, cardiovascular, neurologic, renal and hepatic diseases, severe and inadequately controlled type 1 or 2 diabetes.
-
Recent history or current evidence of bacterial, viral or fungal infection (excluding infections of nailbeds)
-
History of or current active tuberculosis, with typical symptoms of M. tuberculosis infection confirmed by positive results of TB screening test or documented diagnosis prior to screening
-
Latent tuberculosis, as documented in subject's medical records or shown by a positive or indeterminate QuantiFERON test performed at screening, in absence of typical symptoms of tuberculosis. However, a patient with latent tuberculosis may become eligible for the study if he/she meets the following criteria:
-
Patient completed a standard TB prophylaxis prior to the screening and had no active TB or contact with active TB case after completion of the most recent prophylactic regimen OR received at least four weeks of standard TB prophylactic regimen prior to the screening visit and is capable and willing to continue on this regimen while participating in the study.
-
Patient has no active TB at the time of screening, which must be confirmed through referral to a TB specialist if > 1 year has passed since the completion of the last prophylaxis or if the prophylaxis is still being received by the time of screening
-
Patient had no positive findings on chest X-ray examination at screening and within three months prior to screening
-
History of cancer (solid tumors, hematologic malignancies and other) within 5 years of the screening
-
History of significant cytopenia or other disorder of the hematopoietic system
-
Primary or secondary immunodeficiency
-
Any other condition that is listed as a contraindication to receive rituximab or methotrexate therapy
-
Recent use of biologic DMARDs or non-biologic DMARDs other than MTX within the washout periods specified in the study protocol
-
Treatment with any of the authorized or investigational TNF-α inhibitors at any time before the screening (regardless if innovative or biosimilar).
-
History of prior treatment with a B cell modulating or B cell depleting therapy such as, but not limited to, rituximab or other anti CD20 mAb (ocrelizumab, ofatumumab, obinutuzumab), belimumab, atacicept, tabalumab, epratuzumab and other experimental treatments
-
Use of systemic glucocorticoids at a dose higher than 10 mg prednisolone daily or equivalent, within 2 weeks prior to Screening or between screening and Day 1
-
Use of intraarticular hyaluronic acid injection within 28 days before the screening or between screening and Day 1.
-
Use of any drug that has not received regulatory approval for any indication within 4 weeks or a minimum of 5 half-lives, whichever is longer, prior to the Screening Visit or planned receipt of unauthorized drug or vaccine during the study.
-
History of prior allergic or anaphylactic reaction to rituximab therapy (or to any excipient contained in the study IMP)
-
Serious abnormal laboratory findings, specifically:
-
White blood cell count <3,000/μL OR neutrophil count <1,500/μL.
-
Platelet count <75,000/μL.
-
Aspartate aminotransferase or alanine aminotransferase >2.5 times ULN.
-
Hemoglobin <8.0 g/dL.
-
IgG below 5.0 mg/mL or IgM below 0.4 mg/mL.
-
Any other clinically significant laboratory abnormality.
-
Intolerance or contraindications to administration of MTX therapy, i.v. glucocorticoids, or to any other component of the premedication
-
Major surgery (including joint surgery) within 8 weeks prior to Screening or planned surgery within 12 months after baseline
-
Recent vaccination with inactivated/non-live vaccine (<4 weeks prior to study intervention infusion on Day 1) or live vaccine (<6 weeks prior to study intervention infusion on Day 1) vaccine
-
Planned vaccination with live vaccine during the follow-up.
-
Chronic intake of narcotic analgesics (e.g. morphine, fentanyl, hydrocodone, oxycodone, codeine).
-
Participation in a clinical study during the 2 months prior to enrolment in the study (exemption - previously failed screening procedures in MabionCD20-003RA study).
-
Female patients breastfeeding, pregnant or planning of pregnancy within 12 months after the last infusion of the study intervention.
-
Blood donation or other blook loss of more than 500 ml within the last two months prior to Screening Visit.
-
Lack of peripheral venous access.
-
History of drug, alcohol or chemical abuse within 2 years prior to screening.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Mabion SA
- Parexel
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
None provided.- MabionCD20-003RA